Negative pressure wound therapy (NPWT) has become one of the most widely deployed technologies in diabetic foot care. The principle is simple: a foam or gauze filler is sealed into the wound under an adhesive drape, connected to a pump, and held at sub-atmospheric pressure — typically around −125 mmHg, applied continuously or intermittently. The clinical reality is more nuanced. NPWT is not a substitute for debridement, infection control, revascularization, or offloading, and the evidence supporting it is stronger for some indications than others. Understanding where the data are solid and where they are thin is what separates appropriate use from overuse.
How Negative Pressure Is Thought to Work
NPWT acts through several mechanisms at once. Sub-atmospheric pressure draws off exudate and inflammatory mediators, reduces local oedema, and applies mechanical deformation — macrostrain and microstrain — to the wound bed, which stimulates cell proliferation and angiogenesis. The sealed dressing also stabilises the wound environment between changes.
Work published in the Saudi Medical Journal in 2023 gives some biological texture to these effects. In a randomized trial of 100 patients with chronic diabetic foot ulcers, Wu and colleagues found that wounds treated with NPWT before split-thickness skin grafting showed increased blood perfusion, reduced neutrophil extracellular trap formation, and a shift in wound macrophages from the pro-inflammatory M1 phenotype toward the reparative M2 phenotype, compared with alginate dressings. These are the cellular signatures of a wound moving out of stalled inflammation and into a proliferative phase.
What the Trial Evidence Actually Shows
Pooled data are broadly favourable but heterogeneous. A meta-analysis by Chen and colleagues in Annals of Palliative Medicine (2021) combined nine randomized controlled trials totalling 943 patients and reported substantially higher odds of healing with NPWT than with standard care (odds ratio 3.60, 95% CI 2.38–5.45), along with markedly faster granulation tissue formation — a mean difference of roughly nine days. Rates of adverse events and amputation did not differ significantly between groups.
Individual trials echo the granulation finding. In a randomized study of 45 patients with Wagner grade 1 and 2 ulcers published in Diabetes & Metabolic Syndrome, Maranna and colleagues reported greater granulation tissue coverage and ulcer size reduction at 14 days with NPWT, shorter hospital stay (15.7 versus 29.0 days), and complete healing at three months in 90.9% of the NPWT group versus 26.1% of those receiving saline dressings.
The Counterweight: Real-World Results
Results from routine practice have been considerably less impressive. The German DiaFu trial, reported by Seidel and colleagues in BMJ Open (2020), randomized 368 patients across 40 inpatient and outpatient diabetes foot care facilities. In the modified intention-to-treat population of 345 patients, NPWT was not superior to standard moist wound care for wound closure at 16 weeks (absolute difference 2.5%, p = 0.53), and time to closure did not differ. Overall closure rates in both arms were low. Notably, the trial was hampered by substantial protocol deviations and missing documentation, which the authors identified as a factor limiting outcomes — a reminder that device efficacy in a trial protocol and effectiveness in daily practice are different questions.
A 2024 systematic review and meta-analysis in Wounds by Dalmedico and colleagues examined 14 randomized trials and reached a similarly measured conclusion: NPWT showed potential benefit for healing and wound area reduction, but the underlying studies carried notable methodological limitations and clinical heterogeneity.
Where Guidelines Place NPWT
The 2023 International Working Group on the Diabetic Foot (IWGDF) guideline on interventions to enhance ulcer healing, authored by Chen, Game, and colleagues, issued a conditional supportive recommendation for NPWT — specifically for post-operative wounds. The qualifier matters: the guideline emphasises that such adjuncts belong in situations where best standard of care alone has failed to heal the wound and where resources permit. Across all 29 recommendations in that document, the authors noted that the certainty of evidence, while improving, remains poor overall.
Two boundaries are worth underlining. First, the IWGDF/IDSA guidance on diabetes-related foot infection does not recommend NPWT as a treatment for infection itself, given the absence of demonstrated effectiveness for that endpoint. Second, a multidisciplinary consensus published in Burns & Trauma (2021) by Ji and colleagues stressed that irregular or unselected application of NPWT in diabetic foot wounds is associated with complications including bleeding, infection, and tissue necrosis — and that adequate debridement, assessment of perfusion, and appropriate pressure settings are prerequisites, not optional refinements.
Clinical Summary
The most defensible reading of the current literature is that NPWT is a wound bed preparation tool rather than a healing therapy in its own right. It reliably accelerates granulation and shortens the interval to definitive closure procedures such as skin grafting, and it has a favourable safety profile when applied to appropriately selected, adequately debrided, adequately perfused wounds. It performs best in post-operative and post-debridement cavities. It does not treat ischaemia, it does not treat infection, and it does not compensate for inadequate pressure offloading. Real-world trial data suggest that outcomes depend heavily on the quality of the surrounding care pathway — which remains the consistent finding across almost every intervention studied in the diabetic foot.
References
- Chen P, Vilorio NC, Dhatariya K, Jeffcoate W, Lobmann R, McIntosh C, Piaggesi A, Steinberg J, Vas P, Viswanathan V, Wu S, Game F. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2023;40(3):e3644.
- Chen L, Zhang S, Da J, Wu W, Ma F, Tang C, Li G, Zhong D, Liao B. A systematic review and meta-analysis of efficacy and safety of negative pressure wound therapy in the treatment of diabetic foot ulcer. Annals of Palliative Medicine. 2021;10(10):10830–10839.
- Seidel D, Storck M, Lawall H, Wozniak G, Mauckner P, Hochlenert D, Wetzel-Roth W, Sondern K, Hahn M, Rothenaicher G, Krönert T, Zink K, Neugebauer E. Negative pressure wound therapy compared with standard moist wound care on diabetic foot ulcers in real-life clinical practice: results of the German DiaFu-RCT. BMJ Open. 2020;10(3):e026345.
- Dalmedico MM, do Rocio Fedalto A, Martins WA, de Carvalho CKL, Fernandes BL, Ioshii SO. Effectiveness of negative pressure wound therapy in treating diabetic foot ulcers: a systematic review and meta-analysis of randomized controlled trials. Wounds. 2024;36(8):281–289.
- Wu Y, Shen G, Hao C. Negative pressure wound therapy (NPWT) is superior to conventional moist dressings in wound bed preparation for diabetic foot ulcers: a randomized controlled trial. Saudi Medical Journal. 2023;44(10):1020–1029.
- Maranna H, Lal P, Mishra A, Bains L, Sawant G, Bhatia R, Kumar P, Beg MY. Negative pressure wound therapy in grade 1 and 2 diabetic foot ulcers: a randomized controlled study. Diabetes & Metabolic Syndrome. 2021;15(1):365–371.
- Ji S, Liu X, Huang J, et al. Consensus on the application of negative pressure wound therapy of diabetic foot wounds. Burns & Trauma. 2021;9:tkab018.
Comments
